GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Beijing Leadman Biochemistry Co Ltd (SZSE:300289) » Definitions » EBIT

Beijing Leadman Biochemistry Co (SZSE:300289) EBIT : ¥12.8 Mil (TTM As of Mar. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Beijing Leadman Biochemistry Co EBIT?

Beijing Leadman Biochemistry Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ¥0.1 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥12.8 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Beijing Leadman Biochemistry Co's annualized ROC % for the quarter that ended in Mar. 2024 was -106.44%. Beijing Leadman Biochemistry Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 0.04%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Beijing Leadman Biochemistry Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 0.79%.


Beijing Leadman Biochemistry Co EBIT Historical Data

The historical data trend for Beijing Leadman Biochemistry Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing Leadman Biochemistry Co EBIT Chart

Beijing Leadman Biochemistry Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 35.50 -12.23 60.96 -23.88 25.19

Beijing Leadman Biochemistry Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.45 12.23 12.28 -11.77 0.06

Competitive Comparison of Beijing Leadman Biochemistry Co's EBIT

For the Medical Devices subindustry, Beijing Leadman Biochemistry Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beijing Leadman Biochemistry Co's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Beijing Leadman Biochemistry Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Beijing Leadman Biochemistry Co's EV-to-EBIT falls into.



Beijing Leadman Biochemistry Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥12.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beijing Leadman Biochemistry Co  (SZSE:300289) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Beijing Leadman Biochemistry Co's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=-17.84 * ( 1 - -5830.3% )/( (992.691 + 995.188)/ 2 )
=-1057.96552/993.9395
=-106.44 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1938.399 - 90.393 - ( 855.315 - max(0, 106.381 - 1105.683+855.315))
=992.691

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1906.544 - 63.623 - ( 847.733 - max(0, 77.161 - 1086.466+847.733))
=995.188

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Beijing Leadman Biochemistry Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=0.232/( ( (427.678 + max(145.954, 0)) + (413.481 + max(161.281, 0)) )/ 2 )
=0.232/( ( 573.632 + 574.762 )/ 2 )
=0.232/574.197
=0.04 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(149.666 + 88.277 + 10.099) - (90.393 + 0 + 11.695)
=145.954

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(129.037 + 85.077 + 19.914) - (63.623 + 0 + 9.124)
=161.281

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Beijing Leadman Biochemistry Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=12.798/1629.992
=0.79 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beijing Leadman Biochemistry Co EBIT Related Terms

Thank you for viewing the detailed overview of Beijing Leadman Biochemistry Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing Leadman Biochemistry Co (SZSE:300289) Business Description

Traded in Other Exchanges
N/A
Address
No.5 Hongda South Road, Beijing, CHN
Beijing Leadman Biochemistry Co Ltd is a biotechnology company based in China. The company is focusing on research and development, manufacture, and sales of in vitro diagnostic (IVD) products. The company has core competencies in biochemistry, in vitro diagnostic reagents and instruments. Its product offering includes biochemical raw materials such as enzymes, coenzymes, antibodies, buffers, and enzyme substrates; biochemistry diagnostic and companion reagents; and medical test instruments.
Executives
Ding Yao Liang Executives
Wang Xiao Hong Supervisors
Zhang Hai Tao Executives
Zhang Ya Li Supervisors
Sun Qian Director
Wang Jian Hua Directors, executives
Wang Yi Xing Directors, executives
Yang Lu Ping Securities Affairs Representative
Niu Ju Hui Secretary Dong
Zhang Kun Director
Shen Guang Qian Directors, executives
Ma Yan Wen Director
Wang Lan Zhen Directors, executives

Beijing Leadman Biochemistry Co (SZSE:300289) Headlines

No Headlines